Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PALA + fluorouracil
- Development stage
- Unknown
- Lead developer
- PALA Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PALA (N-(phosphonacetyl)-L-aspartic acid) + fluorouracil is a combination therapy that works through biochemical modulation. PALA is an inhibitor of aspartate transcarbamylase that depletes uridine nucleotide pools, which selectively potentiates the antitumor activity of 5-fluorouracil (5-FU) in preclinical models. The combination has been studied in various cancer types including colorectal, pancreatic, and breast cancers with varying response rates.
- Other names
- PALA + 5-FUN-(phosphonacetyl)-L-aspartic acid + 5-fluorouracilPhosphonacetyl-L-aspartate + 5-fluorouracil
02
Targets
TS (Thymidylate synthase)ATCase (Aspartate carbamoyltransferase)
Beyond the preview
Go deeper on PALA + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PALA + fluorouracil.